Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC

NCT03044626 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

101

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma，Non-Small-Cell Lung
Metastatic Lung Cancer
Nonsmall Cell Lung Cancer
Lung Adenocarcinoma Metastatic
Large Cell Lung Carcinoma Metastatic

Interventions

DRUG: Radiotherapy
DRUG: Nivolumab

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]